Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 15;61Suppl 3(Suppl 3):S217-24.
doi: 10.1093/cid/civ615.

T-Cell Therapy: Options for Infectious Diseases

Shreemanta K Parida  1 , Thomas Poiret  2 , Liu Zhenjiang  1 , Qingda Meng  1 , Jan Heyckendorf  3 , Christoph Lange  4 , Aditya S Ambati  5 , Martin V Rao  1 , Davide Valentini  2 , Giovanni Ferrara  6 , Elena Rangelova  7 , Ernest Dodoo  8 , Alimuddin Zumla  9 , Markus Maeurer  2
Affiliations
Review

T-Cell Therapy: Options for Infectious Diseases

Shreemanta K Parida et al. Clin Infect Dis. .

Abstract

The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8(+) and CD4(+) T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy.

Keywords: CAR; Mtb; T-cells; adoptive cell therapy; host-directed therapy.

PubMed Disclaimer

References

    1. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: WHO, 2014.
    1. Parida SK, Axelsson-Robertson R, Rao MV et al. . Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med 2015; 277:388–405. - PubMed
    1. TB Alliance. Pipeline of TB drugs. Available at: http://www.tballiance.org/pipeline/pipeline.php Accessed 8 May 2015.
    1. Zumla A, Chakaya J, Centis R et al. . Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 2015; 3:220–34. - PubMed
    1. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011; 6:e17601. - PMC - PubMed

Publication types

MeSH terms